The FDA has raised concerns about T-cell malignancies in patients receiving CAR-T therapy for hematologic malignancies, citing 20 cases among over 30,000 patients. A recent ASH abstract reported a case of T-cell lymphoma five months after CAR-T treatment for multiple myeloma. However, the authors argue that the risk is low compared to the benefits of CAR-T therapy. They suggest a three-part approach to discuss this issue with patients: first, emphasizing the benefits of CAR-T therapy in improving survival and quality of life; second, noting that other factors like pre-transplant conditioning and medications can contribute to secondary malignancies; and third, explaining that the risk of T-cell malignancies from CAR-T is not significantly higher than in the general population. The authors also highlight that while CAR-T therapy has risks, the benefits far outweigh them, especially for patients with hematologic malignancies. They recommend caution in drawing conclusions from the FDA's statement and emphasize the importance of continued research to identify safer CAR-T insertion sites. Patients should be informed that while the risk exists, the overall benefit of CAR-T therapy is significant. The authors also note that the FDA requires 15 years of follow-up data for CAR-T recipients, which helps minimize the risk of patients being lost to follow-up before diagnosis. Any suspicious post-CAR-T lesions should be biopsied, and any treatment-emergent T-cell malignancies should be reported and analyzed. The authors conclude that current evidence does not support a significant new risk of T-cell malignancies in CAR-T recipients, and the benefits of CAR-T therapy clearly outweigh the risks in patients with hematologic malignancies.The FDA has raised concerns about T-cell malignancies in patients receiving CAR-T therapy for hematologic malignancies, citing 20 cases among over 30,000 patients. A recent ASH abstract reported a case of T-cell lymphoma five months after CAR-T treatment for multiple myeloma. However, the authors argue that the risk is low compared to the benefits of CAR-T therapy. They suggest a three-part approach to discuss this issue with patients: first, emphasizing the benefits of CAR-T therapy in improving survival and quality of life; second, noting that other factors like pre-transplant conditioning and medications can contribute to secondary malignancies; and third, explaining that the risk of T-cell malignancies from CAR-T is not significantly higher than in the general population. The authors also highlight that while CAR-T therapy has risks, the benefits far outweigh them, especially for patients with hematologic malignancies. They recommend caution in drawing conclusions from the FDA's statement and emphasize the importance of continued research to identify safer CAR-T insertion sites. Patients should be informed that while the risk exists, the overall benefit of CAR-T therapy is significant. The authors also note that the FDA requires 15 years of follow-up data for CAR-T recipients, which helps minimize the risk of patients being lost to follow-up before diagnosis. Any suspicious post-CAR-T lesions should be biopsied, and any treatment-emergent T-cell malignancies should be reported and analyzed. The authors conclude that current evidence does not support a significant new risk of T-cell malignancies in CAR-T recipients, and the benefits of CAR-T therapy clearly outweigh the risks in patients with hematologic malignancies.